Core Viewpoint - A class action lawsuit has been filed against Open Lending Corporation for allegedly making materially false and misleading statements regarding its business operations and financial performance during the class period from February 24, 2022, to March 31, 2025 [1][5]. Group 1: Lawsuit Details - The lawsuit claims that Open Lending's defendants misrepresented the capabilities of its risk-based pricing models and issued misleading statements about profit share revenue [5]. - It is alleged that Open Lending's 2021 and 2022 vintage loans were worth significantly less than their outstanding loan balances, and that the underperformance of the 2023 and 2024 vintage loans was misrepresented [5]. - The lawsuit asserts that these misleading statements led to investor damages when the true details about Open Lending's business were revealed [5]. Group 2: Participation Information - Investors who purchased Open Lending securities during the class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2]. - To join the class action, interested parties can visit the provided link or contact the law firm for more information [3]. - A lead plaintiff must move the Court by June 30, 2025, to represent other class members in the litigation [1][3]. Group 3: Law Firm Credentials - The Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements for investors, including over $438 million in 2019 alone [4]. - The firm has been recognized for its success in securities class action settlements, ranking No. 1 in 2017 and consistently in the top 4 since 2013 [4]. - The firm emphasizes the importance of selecting qualified counsel with a proven history in leadership roles within class action lawsuits [4].

NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of NET Power Inc. (NYSE: NPWR, NPWR.WS) between June 9, 2023 and March 7, 2025, both dates inclusive (the “Class Period”). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 17, 2025. SO WHAT: If you purchased NET Power securities during the Class Period you may be entitled to compensation without p ...

NEW YORK, May 02, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Treace Medical Concepts, Inc. (NASDAQ: TMCI) between May 8, 2023 and May 7, 2024, both dates inclusive (the “Class Period”), of the important June 10, 2025 lead plaintiff deadline. SO WHAT: If you purchased Treace Medical securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Perpetua Resources Corp. during the specified Class Period of the upcoming lead plaintiff deadline on May 20, 2025 [1]. Group 1: Class Action Details - Investors who purchased Perpetua securities between April 17, 2024, and February 13, 2025, may be entitled to compensation through a contingency fee arrangement [2]. - A class action lawsuit has already been filed, and interested parties can join by contacting Rosen Law Firm [3][6]. - The lead plaintiff must file a motion with the Court by May 20, 2025, to represent other class members [3]. Group 2: Law Firm Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved significant settlements, including the largest against a Chinese company at the time [4]. - The firm has been ranked No. 1 for securities class action settlements in 2017 and has consistently ranked in the top 4 since 2013, recovering hundreds of millions for investors [4]. - In 2019, the firm secured over $438 million for investors, and its founding partner was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020 [4]. Group 3: Case Specifics - The lawsuit alleges that during the Class Period, Perpetua's Defendants provided misleading information regarding the expected initial capital expenditure for the Stibnite Gold Project, downplaying inflation's impact [5]. - Defendants allegedly concealed material adverse facts about the true costs of the project, leading to artificially inflated security prices for investors [5]. - When the true details were revealed, investors reportedly suffered damages due to the misleading statements made by the Defendants [5].

NEW YORK, April 30, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Sana Biotechnology, Inc. (NASDAQ: SANA) between March 17, 2023 and November 4, 2024, inclusive (the “Class Period”), of the important May 20, 2025 lead plaintiff deadline. SO WHAT: If you purchased Sana securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO ...

NEW YORK, April 29, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of NET Power Inc. (NYSE: NPWR, NPWR.WS) between June 9, 2023 and March 7, 2025, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than June 17, 2025. SO WHAT: If you purchased NET Power securities during the Class Period you may be entitled to compensation without ...

Core Viewpoint - Rosen Law Firm is reminding investors who sold or held shares of Cerevel Therapeutics Holdings, Inc. during a specified period about their potential entitlement to compensation through a class action lawsuit [1][2]. Group 1: Class Action Details - The class period for the lawsuit is from October 11, 2023, to August 1, 2024, and includes those who held shares as of January 8, 2024, and those who sold shares around Bain Capital's purchase on October 16, 2023 [1]. - Investors may join the class action without incurring out-of-pocket fees through a contingency fee arrangement [2]. - A lead plaintiff must be appointed by June 3, 2025, to represent other class members in the litigation [3]. Group 2: Case Allegations - The lawsuit alleges that during the class period, Cerevel's controlling shareholders, Bain Capital and Pfizer, made misleading statements related to a secondary stock offering on October 16, 2023, and a proxy statement on January 18, 2024 [5]. - The secondary stock offering allowed Bain Capital to increase its stake in Cerevel at a discounted price before AbbVie Inc.'s acquisition announcement, which was made 51 days later at $45 per share, nearly double the offering price [5]. - Bain Capital's discounted purchases from the offering resulted in a windfall exceeding $120 million when the acquisition details became public, leading to investor damages [5]. Group 3: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest settlement against a Chinese company at the time and being ranked No. 1 for securities class action settlements in 2017 [4]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [4]. - Many attorneys at the firm have received recognition from Lawdragon and Super Lawyers, emphasizing their expertise in this area [4].

NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Ultra Clean Holdings, Inc. (NASDAQ: UCTT) between May 6, 2024 to February 24, 2025, both dates inclusive (the “Class Period”), of the important May 23, 2025 lead plaintiff deadline. SO WHAT: If you purchased Ultra Clean securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrang ...

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of The Bancorp, Inc. during the specified class period of the upcoming lead plaintiff deadline on May 16, 2025, and highlights the potential for compensation without out-of-pocket costs [1][2]. Group 1: Class Action Details - Investors who purchased Bancorp securities between January 25, 2024, and March 4, 2025, may be eligible to join a class action lawsuit [1]. - A class action lawsuit has already been filed, and interested parties must act by the lead plaintiff deadline [2]. - The lawsuit alleges that Bancorp made false and misleading statements regarding its financial health and risk management practices, particularly concerning its real estate bridge loan portfolio [4]. Group 2: Legal Representation - The Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a proven track record in securities class actions [3]. - The firm has achieved significant settlements in the past, including over $438 million for investors in 2019, and has been recognized for its success in this area [3]. - Investors are encouraged to be cautious in choosing legal representation, as many firms may not have the necessary experience or resources [3].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased securities of Sana Biotechnology, Inc. during the specified Class Period of the upcoming lead plaintiff deadline on May 20, 2025, for a class action lawsuit [1][2]. Group 1: Class Action Details - Investors who bought Sana securities between March 17, 2023, and November 4, 2024, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by May 20, 2025 [2]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company at the time and being ranked No. 1 for the number of settlements in 2017 [3]. - The firm has recovered hundreds of millions of dollars for investors, securing over $438 million in 2019 alone [3]. Group 3: Allegations Against Sana Biotechnology - The lawsuit alleges that during the Class Period, Sana made false or misleading statements regarding its financial stability and the potential of its product candidates [4]. - Specific claims include that Sana was at significant risk of insufficient funds, that certain product candidates were less promising than represented, and that the company was likely to decrease funding for some projects and reduce its workforce [4].